Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Reaffirmed by HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 198.06% from the stock’s current price. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2023 earnings at ($0.88) EPS, Q2 2023 earnings at ($1.13) EPS, Q3 2023 earnings at ($1.52) EPS and Q4 2023 earnings at ($1.32) EPS.

Tarsus Pharmaceuticals Stock Down 2.3 %

Shares of NASDAQ:TARS opened at $13.42 on Wednesday. The company’s fifty day moving average is $15.12 and its two-hundred day moving average is $15.88. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. Tarsus Pharmaceuticals has a 1-year low of $10.80 and a 1-year high of $19.66. The stock has a market capitalization of $357.91 million, a price-to-earnings ratio of -5.26 and a beta of 0.69.

Insiders Place Their Bets

In other news, CFO Leonard M. Greenstein sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $14.56, for a total transaction of $72,800.00. Following the completion of the transaction, the chief financial officer now directly owns 39,289 shares of the company’s stock, valued at $572,047.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bobak R. Azamian sold 4,853 shares of the stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $15.02, for a total value of $72,892.06. Following the sale, the chief executive officer now owns 1,089,253 shares of the company’s stock, valued at approximately $16,360,580.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Leonard M. Greenstein sold 5,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $14.56, for a total transaction of $72,800.00. Following the completion of the sale, the chief financial officer now owns 39,289 shares in the company, valued at $572,047.84. The disclosure for this sale can be found here. Insiders have sold 44,993 shares of company stock valued at $669,816 over the last quarter. Insiders own 24.74% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C acquired a new position in shares of Tarsus Pharmaceuticals during the second quarter worth approximately $19,334,000. Jefferies Financial Group Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth $6,535,000. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 42.7% in the third quarter. Vanguard Group Inc. now owns 935,649 shares of the company’s stock worth $16,018,000 after purchasing an additional 279,826 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at $2,524,000. Finally, State Street Corp raised its stake in shares of Tarsus Pharmaceuticals by 78.0% during the second quarter. State Street Corp now owns 236,516 shares of the company’s stock valued at $3,453,000 after purchasing an additional 103,633 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.